Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?
作者信息
Patel Dipal M, Dahl Neera K
机构信息
Section of Nephrology, Department of Internal Medicine, Yale University, New Haven, Connecticut.
出版信息
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):3-5. doi: 10.2215/CJN.17981120. Epub 2020 Dec 29.
Abstract
摘要
相似文献
1
Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?托伐普坦在常染色体显性多囊肾病中的长期安全性：我们目前的情况如何？
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):3-5. doi: 10.2215/CJN.17981120. Epub 2020 Dec 29.
2
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.托伐普坦在不同慢性肾脏病阶段对常染色体显性遗传性多囊肾病的疗效：TEMPO 3:4试验结果
Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.
3
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.TEMPO（托伐普坦治疗常染色体显性遗传多囊肾病及其结局的疗效和安全性）3-4 研究的原理和设计。
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
4
Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD).病例报告：两名常染色体显性多囊肾病（ADPKD）患者出现托伐普坦相关的肌酸激酶升高。
Eur J Clin Pharmacol. 2020 Oct;76(10):1473-1475. doi: 10.1007/s00228-020-02906-z. Epub 2020 Jun 8.
5
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.托伐普坦：常染色体显性遗传多囊肾病治疗药物的研究进展。
Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x.
6
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.托伐普坦治疗常染色体显性遗传多囊肾病患儿和青少年患者的随机对照试验
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022.
7
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.托伐普坦对常染色体显性遗传性多囊肾病患者的影响：来自TEMPO 3:4试验日本患者亚组的分析
Clin Exp Nephrol. 2015 Oct;19(5):867-77. doi: 10.1007/s10157-015-1086-2. Epub 2015 Feb 7.
8
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.多中心研究托伐普坦在晚期常染色体显性多囊肾病中的长期安全性。
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29.
9
A Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.托伐普坦治疗常染色体显性遗传多囊肾病关键性试验中他汀类药物的使用分析。
Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2.
10
ADPKD, Tolvaptan, and Nephrolithiasis Risk.常染色体显性多囊肾病、托伐普坦与肾结石风险
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):923-925. doi: 10.2215/CJN.07610520. Epub 2020 Jun 11.
引用本文的文献
1
Targeting interleukin-1 signaling for renoprotection.靶向白细胞介素-1信号通路以实现肾脏保护。
Front Immunol. 2025 May 23;16:1591197. doi: 10.3389/fimmu.2025.1591197. eCollection 2025.
本文引用的文献
1
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.多中心研究托伐普坦在晚期常染色体显性多囊肾病中的长期安全性。
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29.
2
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan.托伐普坦治疗常染色体显性多囊肾病患者的生活质量
Kidney Med. 2020 Feb 26;2(2):162-171. doi: 10.1016/j.xkme.2019.11.008. eCollection 2020 Mar-Apr.
3
A Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.托伐普坦治疗常染色体显性遗传多囊肾病关键性试验中他汀类药物的使用分析。
Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2.
4
Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure.肝移植在托伐普坦相关急性肝衰竭中的作用
Kidney Int Rep. 2019 Sep 9;4(11):1653-1657. doi: 10.1016/j.ekir.2019.09.002. eCollection 2019 Nov.
5
Autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病。
Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.
6
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.托伐普坦治疗快速进展型常染色体显性多囊肾病的实用指南。
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.
7
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
8
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.多中心、开放标签、扩展试验，旨在评估托伐普坦早期治疗与延迟治疗对常染色体显性多囊肾病的长期疗效和安全性：TEMPO 4:4试验
Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079.
9
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.常染色体显性多囊肾病患者中托伐普坦相关肝损伤的临床模式：临床试验数据库分析
Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3.
Zotero 插件